Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

Allergan profiles its Ocular Hypotensive Lipids at SOE 1999

Aug. 3, 1999

Alcon describes therapeutic potential of ocular antiinflammatory agents

Aug. 3, 1999

Acadia licenses novel leads for glaucoma therapy to Allergan

July 30, 1999

New muscarinic compounds from Alcon especially useful for Rx of glaucoma

July 29, 1999

New agents for glaucoma disclosed by Alcon in recent patent literature

July 27, 1999

Sunrise LTK System not recommended for FDA approval

July 26, 1999

Alcon's new prostaglandin analogues for glaucoma

July 26, 1999

FDA Advisory Committee votes against recommending Allergan therapy for dry eye disease

July 26, 1999

FDA approves same-day, second-eye treatment with Sunrise LTK system

July 15, 1999

More on PEDF: protein also has ophthalmic indications

July 13, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 16, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...